Pre-Congress Symposium

Youn-Jae Lee (Inje Univ., Korea), Young Oh Kweon (Kyungpook National Univ., Korea), Byung Ik Kim (Sungkyunkwan Univ.)

  • 08:30-08:40
  • Updates on Epidemiology and Natural Course of Viral Hepatitis in Asian-Pacific Region: HBV

    Jeong Eun Song (Daegu Catholic Univ., Korea)

  • 08:40-08:50
  • Updates on Epidemiology and Natural Course of Viral Hepatitis in Asian-Pacific Region: HCV

    Nae-Yun Heo (Inje Univ., Korea)

  • 08:50-09:00
  • Clinical Impacts of Epidemiological Growth of NAFLD in Asian-Pacific Region

    Young Youn Cho (Chung-Ang Univ., Korea)

  • 09:00-09:10
  • Cure of Viral Hepatitis: Definition and Sub-Classification

    Hyun Young Woo (Pusan National Univ., Korea)

  • 09:10-09:20
  • Overview of Barriers to HBV Cure

    Eun Young Cho (Wonkwang Univ., Korea)

  • 09:20-09:40
  • Overview of Barriers to HCV Cure

    Tae-Hee Lee (Konyang Univ., Korea)

  • 09:40-09:50
  • Discussion

  • 10:00-10:20
  • Opening Ceremony


President's Choice Lecture

Si Hyun Bae (The Catholic Univ. of Korea, Korea)

  • 10:20-10:50
  • A Bold Plan to Eliminate Liver Disease

    W. Ray Kim (Stanford Univ., USA)


Symposium 1-1. Hepatitis Elimination by 2030: Where Are We Now?

Diana A. Payawal (Fatima Medical Univ., Philippines), Dong Jin Suh (Daehang Hospital, Korea)

  • 10:50-11:05
  • HBV 2023: New Therapeutic Strategies against an Old Foe

    Sang Hoon Ahn (Yonsei Univ., Korea)

  • 11:05-11:20
  • HCV 2023: The Road to Elimination of HCV

    Yasuhito Tanaka (Kumamoto Univ., Japan)

  • 11:20-11:35
  • Optimizing Hepatitis B and C Treatment in Resource-Limited Settings

    Diana A. Payawal (Fatima Medical Univ., Philippines)

  • 11:35-11:50
  • Global Care Cascade for Chronic Hepatitis B and C Virus Infection

    Ming-Lung Yu (National Sun Yat-sen Univ., Taiwan)

  • 11:50-12:50
  • Luncheon Symposium [Abbvie] AGENDA


State-of-the-Art Lecture I

Masao Omata (The Univ. of Tokyo, Japan)

  • 12:50-13:20
  • A 30-Year Journey of HCV Research: From Discovery to a Cure

    Raymond T. Chung (Harvard Univ., USA)


Keynote Lecture 1. Viral Hepatitis Elimination: Where Do We Stand? It Has Already Reached Halfway by 2030

Chun-Jen Liu (National Taiwan Univ., Taiwan), Kwang Cheol Koh (Sungkyunkwan Univ., Korea)

  • 13:20-13:40
  • Notable Milestones Achieved Towards Viral Hepatitis Elimination to Date

    Jose D. Sollano (The Univ. of Santo Tomas, Philippines)

  • 13:40-14:00
  • Efforts and Strategy to Accelerate Progress Toward Viral Hepatitis Elimination by 2030

    Jinlin Hou (Southern Medical Univ., China)

  • 14:00-14:20
  • It Is Time for a Simplified Approach to Hepatitis B Elimination

    Young-Suk Lim (Univ. of Ulsan, Korea)

  • 14:20-14:40
  • Coffee Break


PG Course 1. On the Way to HBV Elimination, What Is a Recent Issue?

Marc G. Ghany (NIH, USA), George Lau (Humanity and Health Medical Group, Hong Kong), Kwang-Hyub Han (CHA Univ., Korea)

  • 14:40-15:00
  • When to Stop Nucleos(t)ide Analogues: Risks and Benefits

    Jordan Feld (Univ. of Toronto, Canada)

  • 15:00-15:20
  • Application of Current Biomarkers to Guide Anti-HBV Treatment

    Tetsuya Hosaka (Toranomon Hospital, Japan)

  • 15:20-15:40
  • Can Antivirals Reduce Intrahepatic cccDNA and Integrated HBV DNA?

    Marc G. Ghany (NIH, USA)

  • 15:40-16:00
  • Risk of HCC and Biomarkers after a Cure of Hepatitis B

    Jeong Won Jang (The Catholic Univ. of Korea, Korea)

  • 16:00-16:20
  • Coffee Break


PG Course 2. Treatment of Viral Hepatitis, What Progress Being Made?

Raymond T. Chung (Harvard Univ., USA), Ming-Lung Yu (National Sun Yat-sen Univ., Taiwan), Jin Mo Yang (The Catholic Univ. of Korea, Korea)

  • 16:20-16:40
  • Current Optimal Treatment for Chronic HCV Infection in Various Clinical Situations

    Jung Il Lee (Yonsei Univ., Korea)

  • 16:40-17:00
  • Strategies for the Elimination of HCV Infection

    Norah Terrault (Univ. of Southern California, USA)

  • 17:00-17:20
  • Current and Emerging Therapeutic Approaches to Hepatitis C

    Maria Buti Ferret (Hospital Universitario Valle Hebron, Spain)

  • 17:20-17:40
  • HBV-HCV Dual Infection: Changing Epidemiology and Treatment in Asia

    Chun-Jen Liu (National Taiwan Univ., Taiwan)


Joint Symposium (East Asia): HCV Elimination

Lai Wei (Tsinghua Univ., China), Masao Omata (The Univ. of Tokyo, Japan), Sook-Hyang Jeong (Seoul National Univ., Korea)

  • 10:50-11:00
  • Cost-Effectiveness of HCV Screening in Korea: A Step Toward HCV Elimination

    Sook-Hyang Jeong (Seoul National Univ., Korea)

  • 11:00-11:10
  • Clinical Challenges in HCV Management in Japan

    Atsumasa Komori (Nagasaki Univ., Japan)

  • 11:10-11:20
  • How Would China Achieve WHO's Target of Eliminating by 2030?

    Lai Wei (Tsinghua Univ., China)

  • 11:20-11:30
  • Linkage-to-Care and Follow-Up Strategy for HCV Infection in Taiwan

    Tai-Chung Tseng (National Taiwan Univ., Taiwan)

  • 11:30-11:50
  • Discussion

  • 11:50-12:50
  • Luncheon Symposium [Roche] AGENDA

  • 14:20-14:40
  • Coffee Break


Symposium 1-2. Immunology and Immunotherapy of Viral Hepatitis

Hideki Ueno (Kyoto Univ., Japan), Eui-Cheol Shin (KAIST, Korea)

  • 14:40-15:00
  • Immunological Profile of Chronic HBV Infection: Can It Help to Improve Therapeutic Success?

    Antonio Bertoletti (Duke-NUS Medical School, Singapore)

  • 15:00-15:20
  • Immunological Scar after HCV Clearance

    Eui-Cheol Shin (KAIST, Korea)

  • 15:20-15:40
  • T-Cell Responses against Hepatitis Viruses in Human Liver

    Hideki Ueno (Kyoto Univ., Japan)

  • 15:40-16:00
  • Novel Immunological Therapeutics for Cure of HBV Infection

    Wonseok Kang (Sungkyunkwan Univ., Korea)

  • 16:00-16:20
  • Coffee Break


Symposium 1-3. Emerging Antivirals for HBV Cure

Jidong Jia (Capital Medical Univ., China), Seong Gyu Hwang (CHA Univ., Korea)

  • 16:20-16:40
  • Updates on Drugs for HBV Entry and Post-Entry Inhibition

    Hyung Joon Yim (Korea Univ., Korea)

  • 16:40-17:00
  • Updates on HBV Capsid Assembly Inhibitors

    Robert G. Gish (Hepatitis B Foundation, USA)

  • 17:00-17:20
  • Updates on Drugs Targeting HBV RNAs: ASOs and siRNA

    Jidong Jia (Capital Medical Univ., China)

  • 17:20-17:40
  • Updates on cccDNA Disruptors

    Jin-Wook Kim (Seoul National Univ., Korea)

  • 11:50-12:50
  • Luncheon Symposium [Celltrion] AGENDA


SIG 1. Diagnostic and Therapeutic Targets for Virus-Associated HCC

Chul Ju Han (Korea Cancer Center Hospital, Korea), Won Young Tak (Kyungpook National Univ., Korea)

  • 13:20-13:35
  • Novel Blood-Based Biomarkers for Diagnosis of HCC in Chronic Viral Hepatitis

    Jaeyoun Cheong (Ajou Univ., Korea)

  • 13:35-13:50
  • TERT Alterations in Virus-Induced Hepatocarcinogenesis: An Actionable Target?

    Ju Hyun Shim (Univ. of Ulsan, Korea)

  • 13:50-14:05
  • Molecular Signature and Immune Landscape of among HBV, HCV, and Non-Viral HCCs

    Young-Sun Lee (Korea Univ., Korea)

  • 14:05-14:20
  • Differential T-Cell Function between Viral and Non-Viral HCC during Immuno-Oncologic Therapy

    Ji Won Han (The Catholic Univ. of Korea, Korea)

  • 14:20-14:40
  • Coffee Break


Policy Session (*K)

Young-Suk Lim (Univ. of Ulsan, Korea), Jae Young Jang (Soonchunhyang Univ., Korea)

  • 16:20-16:35
  • Introduction of the 1st National Strategic Plan for Viral Hepatitis B & C Control (2023-2027)

    Jin Seon Yang (Korea Disease Control and Prevention Agency, Korea)

  • 16:35-16:50
  • Hepatitis B & C Elimination Strategy in Korea

    Chang Hun Lee (Jeonbuk National Univ., Korea)

  • 16:50-17:05
  • Korean HCV Cohort Study and People Who Inject Drugs (PWID) in Korea

    Gwang Hyeon Choi (Seoul National Univ., Korea)

  • 17:05-17:20
  • Korean HBV Cohort Study

    Jun Yong Park (Yonsei Univ., Korea)

  • 17:20-17:40
  • Panel Discussion

    Speakers & Panelists: In Hee Kim (Jeonbuk National Univ., Korea), Young Chang (Soonchunhyang Univ., Korea)